HK1255598A1 - 咪唑并[4，5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途 - Google Patents

咪唑并[4，5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途 Download PDF

Info

Publication number
HK1255598A1
HK1255598A1 HK18114727.1A HK18114727A HK1255598A1 HK 1255598 A1 HK1255598 A1 HK 1255598A1 HK 18114727 A HK18114727 A HK 18114727A HK 1255598 A1 HK1255598 A1 HK 1255598A1
Authority
HK
Hong Kong
Prior art keywords
compounds
salts
quinolin
imidazo
treating cancer
Prior art date
Application number
HK18114727.1A
Other languages
English (en)
Chinese (zh)
Inventor
Kurt Gordon Pike
Bernard Christophe Barlaam
Thomas Anthony Hunt
Andrew John Eatherton
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1255598A1 publication Critical patent/HK1255598A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18114727.1A 2015-11-03 2016-11-02 咪唑并[4，5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途 HK1255598A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201519406 2015-11-03
GBGB1519406.1A GB201519406D0 (en) 2015-11-03 2015-11-03 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PCT/EP2016/076412 WO2017076895A1 (en) 2015-11-03 2016-11-02 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
HK1255598A1 true HK1255598A1 (zh) 2019-08-23

Family

ID=55130605

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18114727.1A HK1255598A1 (zh) 2015-11-03 2016-11-02 咪唑并[4，5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
HK19100042.7A HK1257678A1 (zh) 2015-11-03 2016-11-02 咪唑并[4，5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK19100042.7A HK1257678A1 (zh) 2015-11-03 2016-11-02 咪唑并[4，5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途

Country Status (20)

Country Link
US (1) US20180318287A1 (enExample)
EP (1) EP3371183A1 (enExample)
JP (1) JP2018536649A (enExample)
KR (1) KR20180070703A (enExample)
CN (1) CN108349971A (enExample)
AU (1) AU2016348546B2 (enExample)
BR (1) BR112018007772A2 (enExample)
CA (1) CA3002608A1 (enExample)
CL (1) CL2018001146A1 (enExample)
CO (1) CO2018003969A2 (enExample)
CR (1) CR20180307A (enExample)
GB (1) GB201519406D0 (enExample)
HK (2) HK1255598A1 (enExample)
IL (1) IL258818A (enExample)
MX (1) MX2018005445A (enExample)
PE (1) PE20181345A1 (enExample)
PH (1) PH12018500958A1 (enExample)
RU (1) RU2018120318A (enExample)
SV (1) SV2018005663A (enExample)
WO (1) WO2017076895A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2019057757A1 (en) 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
ES3001444T3 (en) 2018-09-14 2025-03-05 Suzhou Zanrong Pharma Ltd 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
EP3845532B1 (en) * 2018-09-30 2022-12-21 Medshine Discovery Inc. Quinolino-pyrrolidin-2-one derivative and application thereof
SG11202109451TA (en) * 2019-03-05 2021-09-29 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
WO2021098734A1 (zh) * 2019-11-19 2021-05-27 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor
CN116056698B (zh) * 2020-09-21 2024-11-19 威尚（上海）生物医药有限公司 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes
WO2023143282A1 (zh) * 2022-01-26 2023-08-03 正大天晴药业集团股份有限公司 含有肼基的化合物
US20250179067A1 (en) * 2022-04-11 2025-06-05 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative crystal form, salt crystal form, preparation method and application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311714A1 (en) * 2009-06-04 2010-12-09 Pascal Furet 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
RS62082B1 (sr) * 2015-04-02 2021-08-31 Merck Patent Gmbh Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze

Also Published As

Publication number Publication date
SV2018005663A (es) 2018-07-20
MX2018005445A (es) 2018-08-14
KR20180070703A (ko) 2018-06-26
CN108349971A (zh) 2018-07-31
US20180318287A1 (en) 2018-11-08
CL2018001146A1 (es) 2018-09-04
CO2018003969A2 (es) 2018-07-10
RU2018120318A (ru) 2019-12-05
CR20180307A (es) 2018-10-05
WO2017076895A1 (en) 2017-05-11
JP2018536649A (ja) 2018-12-13
PE20181345A1 (es) 2018-08-22
RU2018120318A3 (enExample) 2019-12-24
CA3002608A1 (en) 2017-05-11
EP3371183A1 (en) 2018-09-12
AU2016348546A1 (en) 2018-06-14
PH12018500958A1 (en) 2018-11-19
HK1257678A1 (zh) 2019-10-25
BR112018007772A2 (pt) 2018-10-30
AU2016348546B2 (en) 2019-05-02
GB201519406D0 (en) 2015-12-16
IL258818A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
HK1255598A1 (zh) 咪唑并[4，5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
CR20200614A (es) Compuestos heterocíclicos como inmunomoduladores
MY197635A (en) Benzooxazole derivatives as immunomodulators
EP4292650A3 (en) Heterocyclic compounds as immunomodulators
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MY192861A (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
MX378957B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
EP4480543A3 (en) Chiral diaryl macrocycle and use thereof in the treatment of cancer
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MX2019004375A (es) Inhibidores de bromodominios.
MX2019004187A (es) Inhibidores de bromodominios.